News & Updates

Long-term exposure to particulate matter ≤2.5 μm (PM2.5) results in increased admission to hospital for COVID-19, according to a recent study.

A decline in daily physical activity (DPA) among patients with idiopathic pulmonary fibrosis (IPF) over a year is noteworthy and disproportionate to a decline in pulmonary physiology, suggests a recent study, noting that this change in DPA may be used as a prognostic tool to assess disease progression.

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.

Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.

New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.

Small airway disfunction can lead to increased airway resistance and visible computed tomography (CT) changes, according to a study. Furthermore, this disease is more common among individuals with advanced age, high body mass index (BMI), childhood cough, and asthma.